Literature DB >> 33546073

The Islanding effect - a special method of percutaneous peritumor ethanol injection for hepatocellular carcinoma: 15-year follow-up outcome.

Ze-Wu Meng1, Xin-Ran Cai, Chang-Zhao Lin, Yan-Ling Chen, Song Liu.   

Abstract

ABSTRACT: Percutaneous ethanol injection is a well-known ablation therapy for hepatocellular carcinoma and is well-tolerated, inexpensive, and effective with few adverse events. In this study, another type of ethanol injection was introduced in the present study.Sixty two patients with hepatocellular carcinoma received 133 percutaneous peritumor ethanol injection treatments and the 15-year follow-up outcomes were analyzed through a collected database.The technical efficiency was 89.5% (119/133 treatments) after the first percutaneous peritumor ethanol injection procedure. However, after the second repeated percutaneous peritumor ethanol injection procedure, technical efficiency increased to 98.5% (131/133 treatments). The 1 year, 3 years, 5 years, 10 years, and 15 years rates of tumor recurrence were 12.9%, 50.0%, 59.7%, 74.2%, and 74.2%, respectively. Multivariate analysis demonstrated that diabetes, Child-Pugh class B, and tumor size greater than 2 cm were significantly related to tumor recurrence. The 1 year, 3 years, 5 years, 10 years, and 15 years rates of overall survival were 98.4%, 83.6%, 61.3%, 19.4%, and 0%, respectively. Multivariate analysis demonstrated that Child-Pugh class B, tumor size greater than 2 cm, and multiple tumors were significantly related to overall survival.Compared with other ablation methods (including peritumor ethanol injection), percutaneous peritumor ethanol injection can avoid tumor ruptures, reduce tumor proliferation and metastasis, and is suitable for the treatment of small tumors. In addition, when combined with other treatment methods, percutaneous peritumor ethanol injection can form a tumor metastatic isolation zone in advance and improve the comprehensive treatment effect.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33546073      PMCID: PMC7837841          DOI: 10.1097/MD.0000000000024365

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  29 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.

Authors:  Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
Journal:  J Hepatol       Date:  2012-11-21       Impact factor: 25.083

3.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

4.  HBV-related HCC, clinical issues and therapy.

Authors:  Massimo Iavarone; Massimo Colombo
Journal:  Dig Liver Dis       Date:  2011-01       Impact factor: 4.088

5.  Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis.

Authors:  T Livraghi
Journal:  Hepatogastroenterology       Date:  2001 Jan-Feb

6.  Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma (3.1-4 cm) and in high-risk locations.

Authors:  Ji-Wei Lin; Chen-Chun Lin; Wei-Ting Chen; Shi-Ming Lin
Journal:  Kaohsiung J Med Sci       Date:  2014-06-02       Impact factor: 2.744

7.  Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.

Authors:  Kaoru Tsuchiya; Yasuhiro Asahina; Nobuharu Tamaki; Yutaka Yasui; Takanori Hosokawa; Ken Ueda; Hiroyuki Nakanishi; Jun Itakura; Masayuki Kurosaki; Nobuyuki Enomoto; Namiki Izumi
Journal:  Liver Transpl       Date:  2014-03       Impact factor: 5.799

8.  Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors.

Authors:  Shuichiro Shiina; Ryosuke Tateishi; Masatoshi Imamura; Takuma Teratani; Yukihiro Koike; Shinpei Sato; Shuntaro Obi; Fumihiko Kanai; Naoya Kato; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  Liver Int       Date:  2012-06-19       Impact factor: 5.828

9.  Observation of the effect of targeted therapy of 64-slice spiral CT combined with cryoablation for liver cancer.

Authors:  Qiao-Huan Yan; Dian-Guo Xu; Yan-Feng Shen; Ding-Ling Yuan; Jun-Hui Bao; Hai-Bin Li; Ying-Gang Lv
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

10.  Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm: A matched case-control comparative analysis.

Authors:  Su Jong Yu; Jung-Hwan Yoon; Jeong Min Lee; Jae Young Lee; Se Hyung Kim; Young Youn Cho; Jeong-Ju Yoo; Minjong Lee; Dong Hyeon Lee; Yuri Cho; Eun Ju Cho; Jeong-Hoon Lee; Yoon Jun Kim; Chung Yong Kim
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more
  1 in total

1.  Two Cases of Paradoxical Nonscarring Alopecia after Mesotherapy with Dutasteride.

Authors:  Leandra Reguero Del Cura; Adrian De Quintana Sancho; Marta Rubio Lombraña; Ana Elisabet López Sundh; Marcos Antonio González López
Journal:  Skin Appendage Disord       Date:  2021-08-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.